Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443058 | 0.76 | CYP2C9 (0.39) | L3MBTL1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL14037264 | 0.72 | CYP2C19 (0.36) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL18871348 | 0.72 | CYP2C9 (0.36) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL2611129 | 0.70 | TSHR (0.39) | L3MBTL1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL6553669 | 0.70 | CYP11B1 (0.39) | CYP19A1 | |
| SCHEMBL25015250 | 0.69 | CYP2C9 (0.38) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL24311782 | 0.69 | CYP2C9 (0.34) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL13944416 | 0.69 | CYP2C9 (0.38) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL19867789 | 0.69 | — | — | |
| SCHEMBL13563919 | 0.68 | TSHR (0.33) | L3MBTL1CYP2C9TSHRCYP2C19MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| EP-4273129-A1 | RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273129-A1 | RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022143771-A1 | RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143771-A1 | RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685363-A | ROR gamma t regulator, preparation method and application thereof | 上海医药集团股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | TP53 232/4885L3MBTL1 2597/4885CYP2C9 1507/4885 |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RORC, RORB, RORA | TP53 2785/4885L3MBTL1 4147/4885CYP2C9 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.